ArticleJournal of translational medicine2026
Gamabufotalin suppresses pancreatic cancer through redox-homeostasis disruption by G6PD downregulation.
Article in Journal of translational medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundPancreatic cancer is a leading cause of cancer-related deaths worldwide, highlighting the critical need for novel therapeutic strategies. Gamabufotalin (CS-6), a bufadienolide compound, has been shown to exert significant inhibitory effects on a variety of cancers.
objectiveThis study investigates the potential therapeutic effects and underlying molecular mechanisms of CS-6 in pancreatic cancer.
methodsThe anti-cancer properties of CS-6 were assessed through both in vivo and in vitro experiments. Network pharmacology and untargeted metabolomics were employed to identify candidate molecular targets of CS-6. Molecular docking, molecular dynamics simulations, and CETSA were used to support potential target engagement between CS-6 and G6PD. G6PD expression was evaluated through public databases and immunohistochemistry. NADPH levels, ROS accumulation, apoptosis, and autophagy were measured using NADPH assays, western blot, flow cytometry, and transmission electron microscopy. Transcriptomic analysis and western blot were conducted to explore the downstream signaling pathways affected by G6PD downregulation.
resultsCS-6 inhibited pancreatic cancer cell growth, migration, and invasion, while promoting apoptosis. In vivo, CS-6 suppressed tumor growth and induced cell death. Elevated G6PD expression in pancreatic cancer was associated with poor prognosis. CS-6 treatment reduced NADPH levels, increased ROS accumulation, and was associated with autophagy induction, accompanied by decreased G6PD protein expression. Furthermore, CS-6 inhibited the PI3K/AKT signaling pathway, and G6PD knockdown recapitulated this effect.
conclusionCS-6 treatment is associated with G6PD downregulation, redox-homeostasis disruption, and suppression of the PI3K/AKT signaling pathway, thereby contributing to autophagy-related cell death, apoptosis, and inhibition of pancreatic cancer progression. These findings highlight CS-6 as a promising therapeutic candidate for pancreatic cancer treatment, with G6PD as a potential molecular target.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.